Please wait...


Generic Name: antihemophilic and von Willebrand factor complex (AN tye HEE moe FIL ik and von WIL e brand FAK tor KOM plex)
Brand Name: Alphanate, Humate-P, Wilate
Physician reviewed Humate-P patient information - includes Humate-P description, dosage and directions.
  • Prescription Settings

Prices and coupons of Humate-p

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Antihemophilic and von Willebrand factors are naturally occurring proteins in the blood that help the blood to clot. A lack of antihemophilic factor VIII is the cause of hemophilia A. A lack of von Willebrand factor is the cause of von Willebrand disease. Humate-P works by temporarily raising levels of factor VIII or von Willebrand factor in the blood to aid in clotting. Humate-P is a combination medicine used to treat or prevent bleeding episodes in people with von Willebrand disease. Humate-P is also used to treat or prevent bleeding episodes in people with hemophilia A. Learn more

Humate-p Side Effects

Humate-P Side Effects

Note: This document contains side effect information about antihemophilic factor / von willebrand factor. Some of the dosage forms listed on this page may not apply to the brand name Humate-P.

For the Consumer

Applies to antihemophilic factor / von willebrand factor: intravenous powder for solution

Along with its needed effects, antihemophilic factor / von willebrand factor may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking antihemophilic factor / von willebrand factor:

More common

  • Difficulty with breathing or swallowing
  • dizziness
  • fast heartbeat
  • fever
  • hives or welts
  • itching
  • nausea
  • reddening of the skin, especially around the ears
  • shortness of breath
  • skin rash
  • swelling of the face, throat, or tongue
  • unusual tiredness or weakness

Incidence not known

  • Cough
  • tightness in the chest
  • vomiting
  • wheezing

For Healthcare Professionals

Applies to antihemophilic factor / von willebrand factor: intravenous powder for injection


The most serious side effects were anaphylaxis/hypersensitivity reactions.


Common (1% to 10%): Allergy, infection, hypersensitivity

Uncommon (0.1% to 1%): Factor VIII inhibition

Very rare (less than 0.01%): Von Willebrand factor inhibition, anaphylactic shock

Frequency not reported: Allergic-anaphylactic reactions, sepsis


Very common (10% or more): Pain (up to 17.5%)

Common (1% to 10%): Fever, surgery, facial edema, chest pain, peripheral edema, rigors

Frequency not reported: Chills, pseudothrombocytopenia, postoperative pain

Postmarketing reports: Fatigue, malaise


Very common (10% or more): Nausea (up to 23.8%), constipation (11.1%)

Common (1% to 10%): Gastrointestinal bleeding, abdominal pain, vomiting

Frequency not reported: Postoperative nausea


Common (1% to 10%): Groin bleed, ear bleed, shoulder bleed, anemia/hemoglobin decreased, thromboembolic event

Frequency not reported: Hemorrhage, hematocrit decreased, postoperative hemorrhage, postoperative wound bleeding

Postmarketing reports: Hemolysis

Nervous system

Common (1% to 10%): Cerebral hemorrhage/subdural hematoma, dizziness, headache, dysgeusia, somnolence

Frequency not reported: Headache, paresthesia, drowsiness


Common (1% to 10%): Epistaxis, hemoptysis, pulmonary embolus, sore throat

Frequency not reported: Respiratory distress

Postmarketing reports: Dyspnea, cough, sneezing, throat irritation


Common (1% to 10%): Sweating increased, pruritus, rash, urticaria


Common (1% to 10%): Menorrhagia, hematuria, urinary retention, urinary tract infection


Common (1% to 10%): ALT increased, liver function test abnormal


Common (1% to 10%): Back pain, muscle and joint stiffness

Frequency not reported: Extremity pain

Postmarketing reports: Joint pain


Common (1% to 10%): Thrombophlebitis

Frequency not reported: Orthostatic hypotension, phlebitis, vasodilation, bradycardia, palpitations


Common (1% to 10%): Infusion site erythema or rash or pain

Frequency not reported: Injection site bleeding

Postmarketing reports: Infusion site pain


Common (1% to 10%): Insomnia


Frequency not reported: Blurred vision


Frequency not reported: Pyelonephritis


Postmarketing reports: Hypervolemia

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Humate-p